Corvus Pharmaceuticals reported that in the blinded, placebo-controlled Cohort 4 study of 24 moderate-to-severe atopic dermatitis patients, oral soquelitinib dosed at 200 mg twice daily achieved a mean 72% reduction in EASI score at eight weeks versus 40% for placebo (p=0.035). Among the 12 treated patients, 75% reached EASI 75, 25% EASI 90 and 33% achieved an IGA score of 0 or 1; 11 of 12 achieved at least EASI 50. By contrast, two placebo patients attained EASI 75 and both required rescue medication due to disease flares, while no active-arm patients did. The data reinforce signals from Cohorts 1–3 and validate eight-week dosing and prior systemic-therapy inclusion (50% of patients in Cohort 4).

No new safety signals emerged during the extended eight-week treatment period. Adverse event rates and laboratory abnormalities were similar between groups, with no hepatic issues or increased infections in the active arm. Corvus highlighted that soquelitinib avoids injection-site reactions and conjunctivitis seen with biologics and noted broader safety experience in T-cell lymphoma trials involving hundreds of patients over months to years without discontinuations due to toxicity. Mechanistically, selective ITK inhibition by soquelitinib is designed to suppress pro-inflammatory Th2/Th17 pathways while preserving Th1 function; early biomarker analyses showed reductions in serum IL-4 (Cohorts 3 and 4) and IL-5 (Cohort 3) and an increase in circulating functional Tregs in Cohort 3, which may underpin response durability.

Corvus plans to initiate a randomized Phase II trial in Q1 2026 enrolling 200 patients across four arms (50 each: 200 mg once daily, 200 mg twice daily, 400 mg once daily and placebo) over 12 weeks, with median EASI reduction as the primary endpoint and off-treatment follow-up. To fund this and other studies—including Phase II asthma and hidradenitis suppurativa trials and a Phase III PTCL registration—Corvus priced an upsized public offering of 7.9 million shares at $22.15 per share, expected to generate approximately $175 million in gross proceeds, plus a 30-day option on an additional 1.185 million shares. Management says this capital provides runway into Q4 2026, with further funding anticipated thereafter.